DURATION OF HUMAN PAPILLOMA VIRUS (HPV) TYPE-SPECIFIC ANTIBODY
DURATION OF HUMAN PAPILLOMA VIRUS (HPV) TYPE-SPECIFIC ANTIBODY
批准号:
8356754
负责人:
William Thomas Shearer
金额:
$0.26万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-12-01 至 2011-11-30
关键词:
12 year oldAgeAntibodiesAntibody FormationChildClinicalClinical ResearchDoseEvaluationFundingFutureGrantHIVHuman PapillomavirusIMPAACTKineticsNational Center for Research ResourcesPlacebosPrincipal InvestigatorProtocols documentationResearchResearch InfrastructureResourcesSafetyScheduleSourceUnited States National Institutes of HealthVaccinesarmboyscohortcostgirlsimmunogenicityplacebo controlled studyresponsetrial comparing
中文摘要
这个子项目是利用这些资源的众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
IMPAACT protocol that utilizes QHPV - P1047 is a closed protocol that is investigating the safety and immunogenicity of QHPV in HIV-infected girls and boys, age 7 to 12 years of age. This study was a placebo-controlled trial that compared a recommended three dose schedule of QHPV in one study arm (Arm A) with an arm that received placebo (Arm B). At 96 weeks after study entry the QHPV recipients (Arm A) received a fourth dose of QHPV and were subsequently evaluated for evidence of an anamnestic antibody response. Also at 96 weeks the previous placebo recipients (Arm B) began the same three dose schedule of QHPV that was administered in Arm A. Thus, two different
cohorts are currently available for future evaluation.
In summary, we seek to determine the long-term durability and kinetics of the vaccine-induced HPV-type-specific antibody and CMI responses in HIV-infected children that were, and are being, immunized in P1047. These subjects are a unique cohort that will
allow us to approach this specific clinical issue.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG
-
批准号:8356662
-
项目类别:
-
资助金额:$4.13万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
A5240 (VERSION 10) A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY
-
批准号:8356728
-
项目类别:
-
资助金额:$2.64万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
IMPAACT 1077HS (VS 10) HAART STANDARD VERSION OF THE PROMISE STUDY
-
批准号:8356740
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
Baylor College of Medicine Clinical Trial Unit
-
批准号:8138733
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC
-
批准号:8356681
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN
-
批准号:8356734
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
PH 201 MEMORY FUNCTIONING IN CHILDREN AND ADOLESCENTS WITH PERINATAL HIV
-
批准号:8356748
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1088 (VERSION 10) A PHASE II STUDY TO ASSESS THE SAFET
-
批准号:8356737
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1066 (VERSION 10) A PHASE I/II, MULTICENTER, OPEN-LAB
-
批准号:8356688
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)
-
批准号:8356682
-
项目类别:
-
资助金额:$8.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10
-
批准号:8356654
-
项目类别:
-
资助金额:$11.17万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
A5241 (VERSION 10) THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS
-
批准号:8356712
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF Q
-
批准号:8356683
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
IMPAACT P1089 (VERSION 10) A LABORATORY STUDY TO ASSESS THE IMMUNOGENICITY
-
批准号:8356738
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
Clinical Research Core
-
批准号:7930006
-
项目类别:
-
资助金额:$24.01万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL
-
批准号:8166651
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN
-
批准号:8166748
-
项目类别:
-
资助金额:$1.24万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC
-
批准号:8166692
-
项目类别:
-
资助金额:$9.72万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QU
-
批准号:8166695
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG
-
批准号:8166661
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: